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ABSTRACT
Polymeric nanocarriers improve cellular uptake, stability, solubility, and functionality of
entrapped drugs and nutraceuticals. The hypothesis of this study was that entrapping
lutein, a hydrophobic antioxidant, in different polymeric nanoparticles (NPs) will
improve its stability and antioxidant activity. The following objectives were proposed: 1.
Synthesize and characterize polymeric nanoparticles of poly lactic co-glycolic acid
(PLGA) and PLGA NPs covered with a layer of chitosan (PLGA/Chi) from a
physicochemical perspective, and 2. Assess functionality of the entrapped lutein as a
function of type of polymer in which entrapped. Nanoparticles were synthesized by
emulsion evaporation method. Characterization included size, zeta potential, and
morphology measurement, followed by testing the physical and chemical stability, and
antioxidant activity of entrapped lutein. PLGA NPs loaded with lutein were in the size
range of 119.2 nm ± 0.98 nm with a PDI of 0.17± 0.02 and a zeta potential of – 29 mV ±
1.1 mV in nanopure water with 0.05 mg PVA/ mg PLGA ± 0.002 mg PVA/ mg PLGA
remaining on the surface of the nanoparticles. PLGA/Chi NPs loaded with lutein were in
the size range of 145.9 ± 0.3 nm with a PDI of 0.25 ± 00.01 and a zeta potential of 21.2
mV ± 2.3 mV with 0.06 mg ± 0.002 mg PVA/ mg PLGA/Chi remaining in nanopure
water. PLGA NPs and PLGA/Chitosan NPs loaded with lutein were stable in emulsions
made with Tween 20 for 72 hours at 37 °C as indicated by a constant size over time.
PLGA and PLGA/Chi NPs protected the chemical stability of lutein in Tween 20
emulsions for 24 hours at 37 °C. PLGA and PLGA/Chitosan NPs showed significant
reductions in the oxidation of cholesterol by 45 ± 1% and 60 ± 1 % at 48 hours, and 36 ±
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1 % and 42 ± 3 % at 72 hours when compared to the free lutein. The addition of chitosan
to the PLGA NPs further enhanced the efficacy of lutein as an antioxidant when
compared to PLGA NPs. These results support the hypothesis that polymeric NPs are
enhancing stability and antioxidant activity of entrapped lutein and hence may find
beneficial applications in the biomedical and food science fields for delivery of lutein.
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CHAPTER 1: INTRODUCTION
Antioxidants protect carbohydrates, proteins, nucleic acids and lipids from
oxidation, for improved overall health of the consumer. Reactive oxygen species (ROS)
and reactive nitrogen species (RNS) cause oxidation of carbohydrates, proteins, and other
molecules which is associated with diseases such as cardiovascular and inflammatory
diseases, cancer, and premature aging. Mechanisms of oxidation occur through altering
the chemical structure of lipids and other molecules inside the body. Natural defenses in
the human body are designed to combat this oxidation; these defenses include natural
antioxidants such as glutathione, bilirubin, α-tocopherol, and many others (Laguerre,
Lecomte et al. 2007). However, the human body does not contain enough of these natural
antioxidants to maintain a balance sufficient to diminish all oxidative stress (Laguerre,
Lecomte et al. 2007). Therefore dietary antioxidants are necessary for protection against
diseases and inflammation. Common exogenic dietary antioxidants include tocopherols,
tocotrienols, flavonoids, and carotenoids (Laguerre, Lecomte et al. 2007).
Many of these dietary antioxidants such as carotenoids and tocopherols are lipid
soluble, which results in low bioavailability in vivo (Anand, Nair et al. 2010). These
molecules are often photosensitive and easily oxidized leading to a further decrease in
bioavailability and in vivo activity of these molecules (Canene-Adams and Erdman
2009). A well-investigated solution for enhanced stability and bioavailability is the use of
antioxidant nanoparticles as delivery systems (Choi, Zuckerman et al. 2011), (Faraji and
Wipf 2009).
In particular, polymeric nanoparticles made of polymers such as poly (lactic-coglycolic) acid (PLGA), poly-lactic acid (PLA), polyethylene glycol (PEG), zein, and low
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molecular weight chitosan (LMWC) have shown to improve the bioavailability of various
hydrophobic drugs and nutraceuticals (Arunkumar, Harish Prashanth et al. 2013),
(Kumari, Yadav et al. 2010), (Anand, Nair et al. 2010), (Hu, Lin et al. 2012), (Hu, Liu et
al. 2011) and provide protection from degradation of multiple photosensitive and unstable
antioxidants (Trombino, Cassano et al. 2009), (Konecsni, Low et al. 2012). Nanodelivery
systems may also enhance activity of bioactives in vivo through their controlled release
properties (Kumari, Yadav et al. 2010), (Hu, Liu et al. 2011), (Hu, Lin et al. 2012).
Nanoparticle behavior in vivo is affected by the properties of the particle,
including size and surface charge (Mohamed and van der Walle 2008). Surfactants such
as poly vinyl alcohol (PVA, Figure 1.1) are commonly used to enhance these properties
(Mohamed and van der Walle 2008), (Sahoo, Panyam et al. 2002), (Astete, Kumar et al.
2007). Concentration of surfactant will affect the properties of size, zeta potential, and
hydrophobicity of NPs and can be adapted for specific applications (Sahoo, Panyam et al.
2002).

Figure 1.1 Structure of poly (vinyl alcohol)

Polymers selected for nanoparticle synthesis largely contribute to nanoparticle
properties and their activity in vivo. Poly (lactide co glycolide), PLGA, (Figure 1.2), for
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example, is a FDA approved, biodegradable synthetic co-polymer of lactic acid and
glycolic acid shown to improve stability and bioavailability of entrapped drugs (Anand,
Nair et al. 2010),(Astete, Kumar et al. 2007). It is a highly biocompatible and
biodegradable polyester (des Rieux, Fievez et al. 2006). PLGA is soluble in many
different solvents, and is available in many different formulations so hydrophobicity of
the NP can be optimized through ratio of lactic acid to glycolic acid of the PLGA selected
for NP synthesis (Makadia and Siegel 2011).

Figure 1.2: PLGA Structure

Chitosan (chi), (Figure 1.3), a natural heteropolymer derived from chitin, is commonly
used to supply a positive surface charge to a nanomaterial. Chitosan has been found to
provide a stable means of encapsulation and to the positive zeta potential of the Chitosan
NP was shown to improve cellular uptake of nanoparticles (Hu, Ting et al. 2012),(He, Hu
et al. 2010).

Figure 1.3: Low molecular weight chitosan structure
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In the present study lutein was entrapped in PLGA and PLGA/Chitosan nanoparticles
using PVA as a surfactant in an attempt to improve its efficacy as an antioxidant against
peroxyl radicals. Chapter 2- Nanodelivery of Bioactive Components for Food
Applications: Types of Delivery Systems, Properties, and their Effect on ADME Profiles
and Toxicity of Nanoparticles and will further describe how different nanoparticle
properties affect nanodelivery and functionality of the entrapped bioactive. Chapter 3
covers the synthesis and characterization of PLGA (lutein) and PLGA/Chitosan (lutein)
NPs and compares the antioxidant functionality of nanoentrapped lutein to antioxidant
lutein. Chapter 4 summarizes the findings of this study.
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CHAPTER 2: NANODELIVERY OF BIOACTIVE COMPONENTS FOR FOOD
APPLICATIONS: TYPES OF DELIVERY SYSTEMS, PROPERTIES, AND THEIR
EFFECT ON ADME PROFILES AND TOXICITY OF NANOPARTICLES

Introduction
Antioxidants, probiotics, polyunsaturated fatty acids, and proteins are common bioactives
that can be added to food to improve nutritional value. Food bioactives can be used to
prevent diseases such as cancer and heart disease and to improve overall health(Jime ́nezColmenero2013). Nanodelivery of these components in food may improve their stability
(Trombino et al. 2009), solubility (Fathi et al. 2011), functionality (Swarnakar et al.
2011), cellular uptake (Gaumet et al. 2010, Hamdy et al. 2009, Harush-Frenkel et al.
2007, Hu et al. 2012, Li et al. 2010, Sahoo et al. 2002, Win & Feng 2005, Wang et al.
2012, Yoo & Mitragotri 2010, Zhang et al. 2008), and bioavailability (Anand et al. 2010)
and may also provide controlled release (Kumari et al. 2010) for better efficacy of the
bioactive.
“This chapter previously appeared as [T. Borel and C.M. Sabliov, Nanodelivery of
bioactive components for food applications: types of delivery systems, properties, and
their effect on ADME profiles and toxicity of nanoparticles in Annual Reviews of Food
Science and Technology February 2014]. It is reprinted by permission of [Annual
Reviews].”

It is therefore widely accepted that nanoparticles may offer distinct advantages for
delivery of bioactives, ranging from improving stability to controlling the release and

8

targeting of the bioactive for enhanced functionality. Due to the increasing interest in the
use of nanoparticles for food and oral drug delivery, consumer safety has become a
serious concern (Vega-Villa et al. 2008). Safety concerns stem from the potential of the
nanoparticles to translocate to tissues due to their small size and the higher-thanphysiologically normal concentrations of the delivered bioactive in tissues. The type of
nanoparticle and related chemical, physical, and morphological properties affect their
interaction with living cells and also determine the route of clearance from the
gastrointestinal (GI) system and possible toxic effects.

Types Of Delivery Systems
Nanodelivery systems (Figure 1) are classified into two main groups, liquid and solid.
The three types of liquid nanodelivery systems are nanoemulsions, nanoliposomes, and
nanopolymersomes. Nanoemulsions can be separated into either emulsions or stabilized
emulsions. The three types of solid nanodelivery systems are lipid nanoparticles,
polymeric nanoparticles, and nanocrystals. The group of lipid particles is composed of
solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Polymeric
nanoparticles can take the form of nanospheres and nanoencapsulates.

Emulsions and Stabilized Emulsions
In its most simple form, an emulsion is the mixture of two immiscible liquids, generally
oil and water. Nanoemulsion droplets measure between 10 and 100 nm in diameter and
are typically transparent due to these sizes being on a scale smaller than the ultravioletvisible light range. Emulsions stabilized by surfactants or other types of stabilizing
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agents, including phospho- lipids, amphiphilic proteins, or polysaccharides (Guzey &
McClements 2006), namely stabilized.

Figure 1: Classification of nanodelivery systems. Abbreviations: MLVs, multilamellar
vesicles; SLVs, single lamellar vesicles
emulsions, have been developed to provide controlled release, improved entrapment
efficiency, and protection from degradation (Carrillo-Navas et al. 2012, McClements &
Li 2010). In the instance of nanodelivery, the hydrophobic food bioactive is to be
dissolved in the internal organic phase of an oil-in-water emulsion, whereas double
emulsions are employed for delivery of hydrophilic molecules (Sapei et al. 2012).
Two types of methods are commonly used in nanoemulsion synthesis, mechanical or
chemical processes. Mechanical processes employing sonicators and microfluidizers are
considered high- energy processes as mechanical forces are employed to break larger
emulsion droplets into smaller ones. Low-energy or chemical methods result in
spontaneous formation of emulsion droplets due to the hydrophobic effect of lipophilic
molecules, in the presence of emulsifiers (McClements & Li 2010). Emulsions and
stabilized emulsions are commonly used in the food industry. Emulsions of olive oil
stabilized with sodium caseinate, whey protein concentrate, and polyglycerol ester were
used to replace the animal fat in meat products (Cofrades et al. 2013); locust bean gum
was used for reduced-fat salad dressings and desserts (Chung et al. 2013); additionally,
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lemon oil emulsions are being developed for food and beverage flavorings (Rao &
McClements 2012).

Liposomes
Liposomes are self-assembled nanoparticles formed from phospholipids in the form of a
bilayer. Liposomes are ideal for carrying hydrophilic molecules due to the polar
environment of the vesicle (Tamjidi et al. 2013). However, hydrophobic molecules can
be delivered using liposomes as well, when these components are entrapped in the
bilayer. When delivered with liposomes, the encapsulated materials are protected from
external conditions. Another advantage is that liposomes can be made without the use of
organic solvents (Madrigal-Carballo et al. 2010). Liposomes can be either unilamellar or
multilamellar, referred to as small unilamellar vesicles (SUVs) and multilamellar large
vesicles (MLVs), respectively. SUVs are in the range of 100 nm, whereas MLVs are
commonly between 500 nm and 5 µm.
Methods for synthesizing liposomes include the gentle hydration method (Wang et al.
2010) and the layer-by-layer electrostatic deposition (Madrigal-Carballo et al. 2010).
Liposomes have been developed for food applications as a method for creating ironenriched milk (Xia & Xu 2005), antioxidant delivery (Madrigal-Carballo et al. 2010), and
codelivery of vitamins E and C with orange juice (Marsanasco et al. 2011).

Polymersomes
Polymersomes are vesicles formed from a bilayer of amphiphilic copolymers with
bioactives en- trapped in the formed cavity (Bouwmeester et al. 2009), similar to
liposomes. The difference is that a copolymer of amphiphilic nature is used instead of
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phospholipids. Similarly to liposomes, Polymersomes can be used to entrap both
hydrophilic and hydrophobic drugs. Advantages of polymer carriers, as opposed to lipid
carriers, include controlled release and increased stabil- ity and versatility (Rastogi et al.
2009). Polymersomes can be made with tri-block copolymers such as poly(caprolactone)poly(ethylene glycol)-poly(caprolactone) and can be synthesized using methods similar
to those used for polymeric nanoparticles (Rastogi et al. 2009).

Nanocrystals
Nanocrystals consist of a bioactive surrounded by a surfactant (Florence 2005).
Nanocrystals improve the solubility of poorly water-soluble drugs by increasing the
surface-area-to-volume ratio, which increases the dissolution rate of the bioactive in vivo
(Sun & Yeo 2012). The distinct advantage of nanocrystals is that they have 100%
bioactive loading. Another advantage is that they can be prepared without organic
solvents. Nanocrystals have shown not only improved solubility but also improved
cellular interaction of the bioactive in nanocrystal form (Hunter et al. 2012).
Nanocrystals can be made using mechanical or chemical methods (Sun & Yeo 2012).
Starch nanocrystals are commonly prepared using acid hydrolysis, ultrasonication, and
stirring to disperse and prevent the nanocrystals from aggregating (Kristo & Biliaderis
2007, Xu et al. 2010). Wet milling is applied to reduce the size and increase the
uniformity of the crystals (Sun & Yeo 2012). Another technique of forming nanocrystals
is nanoprecipitation (Sun & Yeo 2012). Food grade starch and protein nanocrystals are
being developed for various applications in the food and biomedical realms (de Mesquita
et al. 2012, Flauzino Neto et al. 2013, Tzoumaki et al. 2011).
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Lutein nanocrystals for oral delivery are in the process of development, but lutein
crystals in the 100-nm range have not yet been achieved (Mitri et al. 2011).

Lipid Nanoparticles
SLNs are similar to emulsions, with the exception that the lipids are in a solid phase. The
lipids in these SLNs are digested at a slower rate than lipids in a liquid phase
(McClements & Li 2010). An advantage of SLNs is that they provide a means of
entrapping lipophilic molecules in stable particles without the use of organic solvents.
SLNs have the potential to provide controlled release of various lipophilic components
due to decreased mobility of the bioactive in the solid matrix (Mehnert & Ma ̈der 2012).
However, these particles have a low loading efficiency and drug may be expelled during
crystal structure transformation during storage (Tamjidi et al. 2013). NLCs are lipid
nanoparticles with both crystallized and liquid phases of lipid used for nanodelivery
(Tamjidi et al. 2013). The inner liquid phase dissolves and entraps the bioactive to
provide the advantages of chemical stability, controlled release, and a higher loading
efficiency (Tamjidi et al. 2013).
High-energy methods are often used to synthesize SLNs and NLCs for food applications
(McClements & Li 2010, Tamjidi et al. 2013), including microfluidization and
ultrasonication (Mehnert & Ma ̈der 2012). Hot and cold homogenization techniques are
able to form both SLNs and NLCs (Tamjidi et al. 2013). SLNs are often varied in size
depending on the surfactant type and concentration; if the surfactant concentration is too
low or too high, the SLNs will aggregate. The use of ionic surfactants often results in
smaller particle sizes, and stability is increased by using more than one surfactant to
stabilize the emulsion (Mehnert & Ma ̈der 2012). SLNs were developed for food
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applications with the goal of improving guava shelf life (Zambrano-Zaragoza et al. 2013),
the stability of quercetin (Li et al. 2009), beta carotene, and alpha tocopherol (Trombino
et al. 2009).

Polymeric Nanoparticles
Polymeric nanoparticles are matrices of polymers and entrapped molecules surrounded
by an emulsifier or surfactant (des Rieux et al. 2006, Hunter et al. 2012, Plapied et al.
2011). Polymeric nanocapsules are nanoparticles in which the polymer forms a wall
surrounding the entrapped core containing the bioactive; the polymer encapsulates the
bioactive. These particles, nanospheres, and nanocapsules are designed to protect the
entrapped bioactive from degradation (Mishra et al. 2010); polymeric particles can be
engineered to have mucoadhesive or enhanced intestinal permeability (Chen et al. 2011).
Methods of synthesizing polymeric nanoparticles include solvent displacement or
nanoprecip- itation or desolvation, salting out, and emulsion evaporation methods
(Sabliov & Astete 2008). Other methods are pH cycling, thermal treatment, atomization
spraying, and the use of super- critical fluids; these are mostly applied to nanoparticle
synthesis for proteins and hydrocolloids. Natural polymer nanoparticles such as gum
arabic maltodextrin were developed to improve the stability and bioavailability of
epigallocatechin gallate (Peres et al. 2011). Protein polymer (zein) nanoparticles
successfully entrapped essential oils with antioxidant properties (Wu et al. 2012). Gelatin
nanoparticles encapsulated polyphenol antioxidants to protect their antioxidant activity
and provide controlled release (Shutava et al. 2009).
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Properties of Nanodelivery Systems of Importance to Nano-Bio Interactions
Physicochemical properties of the delivery systems will affect their absorption,
distribution, metabolism, and excretion (ADME), which is essential in modulating the in
vivo activity of the delivered bioactive. Properties of importance in nanoparticle in vivo
interactions are size, charge, hydrophobicity, and targeting properties, among others
(Figure 2).
Size is important for entry into cells, immune cell stimulation, and particle clearance
(Naahidi et al. 2013). Cell uptake mechanisms are partially dependent on size.
Endocytosis is the process through which nanoparticles or small molecules enter cells;
the specific type of endocytosis through which the nanoparticle enters the cell determines
the translocation of the entrapped molecule inside the endosome (Sahay et al. 2010). The
common sizes of vesicles formed through endocytosis are between 60 nm and 1,000 nm.
Particles larger than 500 nm are not endocytosed by enterocytes; therefore, they are
commonly excreted before reaching the bloodstream (Table 1) (Yoo & Mitragotri 2010).
The size of particles may affect the immune response; the larger the particle, the more
likely it is to be eliminated by cells in the mononuclear phagocyte system (MPS), which
will reduce the nanoparticle blood circulation time (Choi et al. 2011). Nanoparticles between 1 and 20 nm remain in the vasculature longer than larger particles; particles
between 30 and 100 nm are able to evade the MPS and avoid clearance by macrophage
cells, allowing for long circulation times (Table 1) (Faraji & Wipf 2009).
Hydrophobicity affects cellular uptake, distribution, interaction with immune cells and
plasma proteins, and clearance from the body (Naahidi et al. 2013). Hydrophobic
nanoparticles diffuse
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Figure 2: Chemical, physical and morphological properties and their effect on in vivo
interactions. Reprinted with permission from Macmillan Publishers, Ltd. (Nature),
copyright 2013 (Naahidi 2013).

into epithelial cells more easily than hydrophilic particles because of a large activity
coefficient (Table 1) (Acosta 2009, Powell et al. 2010). Hydrophobic nanoparticles are
recognized as foreign substances by macrophages of the MPS present in the blood and
are often cleared through biliary excretion (Table 1) (Bertrand & Leroux 2012, Naahidi et
al. 2013).
Hydrophilic nanoparticles may be quickly cleared from the kidney if they are smaller
than 10 nm (Table 1) (Choi et al. 2011). Hydrophilic nanoparticles are less likely to be
recognized as foreign objects in the blood (Naahidi et al. 2013). Hydrophilic
nanoparticles traverse through mucus at a rate faster than that of hydrophobic particles
due to hydrophobic interactions in the mucus layer (Lai et al. 2009).
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Table 1: Ranking of characteristics for absorption, distribution, and excretion
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Table 1 (Continued)

Charge is important for entry into cells, immune cell stimulation, plasma proteins, and
toxic- ity (Naahidi et al. 2013). Positive charges are more prone to promote an immune
response than negative and neutral charges (Table 1) (Bertrand & Leroux 2012, Naahidi
et al. 2013). Nanopar- ticles without charge are able to remain in the bloodstream for a
longer time than positively or negatively charged particles, and negative charges are
associated with longer circulation times in mice than positive charges (Bertrand &
Leroux 2012).
Targeting affects nanoparticle distribution and immune response (Naahidi et al. 2013).
Targeting molecules may exploit receptors to gain entry into specific types of cells
(Markovsky et al. 2012).
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The physical and chemical properties, specifically size and surface charge, of the
targeting molecule affect its immune response (Markovsky et al. 2012).

Adsorption, Distribution, Metabolism, And Excretion (ADME) of Nanoparticles
The ADME profile of a nanoparticle is greatly determined by properties such as size,
charge, hydrophobicity, and targeting molecules, and these properties are dependent on
the type of delivery system (Card et al. 2011). Nanoparticle ADME (Figure 3) will
determine the potential toxicity.

Figure 3: Flow chart describing a nanoparticle’s path through the body from ingestion to
excretion
of the nanoparticle (Bouwmeester et al. 2009). Absorption refers to the nanoparticle
interaction with the gut mucosa and epithelial cells, which ends in the nanoparticle
entering into systemic circulation. Distribution or biodistribution occurs through systemic
circulation, during which the particles are distributed to organs such as the liver, kidneys,
spleen, heart, lungs, and brain. Metabolism describes the biotransformation of the
nanoparticle that occurs through interactions with proteins and lipids in tissues such as
the liver and intestinal tissue.
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The liver, kidneys, and colon are primarily responsible for excretion of nanoparticles and
their metabolites (Bertrand & Leroux 2012, Bouwmeester et al. 2009).

Ingestion
Knowledge of the fate of nanoparticles in the GI tract is needed to optimize delivery
systems for improvement of bioavailability of food nutraceuticals. Ingested nanoparticles
begin their GI journey when they enter the mouth and are partially digested through
saliva and mastication at a pH between 5 and 7 (McClements & Li 2010). Then the
nanoparticles enter the stomach through the esophagus, where they will remain for 30
min to 4 h, depending on whether the stomach is in a fasting or fed state (Kompella &
Lee 2001, McClements & Li 2010). The acidic pH of the stomach (between 1 and 2),
along with enzymes, is designed to break down proteins and carbohydrates (Ensign et al.
2012). If the nanoparticle is made out of hydrocolloids and proteins, degradation of the
nanoparticles can be significant under the extreme pH of the stomach. Assuming that the
particles are able to withstand the acidic pH and remain suspended in the media as an
integral nanoparticle, they travel to the small intestine. Nanoparticles enter the intestines
through the duodenum, where they are introduced to a pH between 6 and 7.5 and various
bile salts from the gall bladder that are designed to emulsify fats (Kompella & Lee 2001,
McClements & Li 2010). Nanoparticles remain in the small intestines for 3–6 h before
traveling to the large intestine or colon (Kompella & Lee 2001, McClements & Li 2010).
It is mainly in the small intestine that the nanoparticle and/or the released bioactive are
absorbed.
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Absorption
For nanoparticles to be absorbed, they have to overcome enzymes, the low pH of the
stomach, the mucosal lining of intestines, and the cellular membranes with selective
permeability (Chen et al. 2011, Ensign et al. 2012). The inner surface of the small
intestine contains epithelial cells for the uptake of necessary nutrients or nanoparticles.
These cells are covered in microvilli and mucus to help them absorb various nutrients and
avoid absorption of harmful chemicals. Enterocytes in the small intestine are covered
with a thin layer of firmly adherent mucus and a thick layer

Figure 4: Mechanisms of entry into cells (Sahay et al. 2010). Abbreviations: CCVs,
clathrin-coated vesicles; CLICs, clathrin-independent carriers; GEEC,
glycosylphosphatidylinositol-anchored protein-enriched compartment. Reprinted from J.
Control. Release, Vol 145(3), Guarav Sahay, Daria Y. Alakhova, Alexander V. Kabanov,
Endocytosis of Nanomedicines, Page 14, Copyright (2010), with permission from
Elsevier.
of loosely adherent mucus making it the easier for nutrients to be absorbed (Ensign et al.
2012). The surface properties and concentration of the particles determines the type of
transport and extent of nanoparticle absorption. The optimal size for mucous transfer is
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less than 100 nm, which is the average pore size of human mucus (Lai et al. 2007, 2009).
However, a nanoparticle size of 200 nm is preferred over one of 100 nm because 200-nm
nanoparticles have three times the diffusion coefficient of 100-nm nanoparticles (Acosta
2009) (Figure 3). The size cutoff for mucosal transfer is approximately 500 nm (Norris et
al. 1998). M cells in Peyer’s patches make up approximately 1% of intestinal cells, and
they are able to absorb large particles of approximately 1 µm as well as small particles of
approximately 100 nm. Particles may enter M cells through endocytosis such as clathrinmediated endocytosis or fluid-phase endocytosis (Florence 2005). Enterocytes are
responsible for the rest of the cellular uptake in the intestine through clathrin- mediated
endocytosis, caveolea-mediated endocytosis, macropinocytosis, caveolea, and clathrinindependent endocytosis (Figure 4) (Sahay et al. 2010). Nanoparticles endocytosed via
clathrin- mediated endocytosis enter early endosomes with a low pH and eventually enter
lysosomes in which they will be metabolized. Nanoparticles that enter cells via caveoleamediated endocytosis are enveloped in caveosomes, which enter the nucleus.
Nanoparticle transport through cellular membranes and organelles is dependent on cell
type, surface charge, nanoparticle composition, and hydrophobicity. Nanoparticle path
and localization within the cellular environment will be responsible for functionality of
the entrapped bioactive.

Distribution and Metabolism
Following absorption through the gut, very hydrophobic nanoparticles are transported to
the lymph, if they are taken up in the gut-associated lymphoid tissue and reach lymphoid
circulation (Bouwmeester et al. 2009); alternatively, particles can be sent to the liver via
the hepatic portal vein, if they are not taken up by the gut-associated lymphoid tissue.
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The liver is where they are processed and sent to systemic circulation (Chen et al. 2011)
(Figure 3).
If the nanoparticles enter the lymph, they will reach circulation before being metabolized
in the liver (Hunter et al. 2012). This is one way that nanoparticles are able to bypass
first-pass metabolism and increase concentration of bioactives in the bloodstream. The
lymphatic system delivers the nanoparticles to systemic circulation through the caudal
vena cava (Lu et al. 2010). Upon reaching systemic circulation, nanoparticles are
transported to various organs such as the heart, lungs, spleen, kidney, liver, and
potentially the brain (Aillon et al. 2009). Organs with higher blood flow such as those
listed above are exposed to higher concentrations of nanoparticles (Faraji & Wipf 2009).
The metabolism of nanoparticles greatly depends on the type of nanoparticle. Polymeric
and lipid nanoparticles are often designed to be biodegradable. Natural polymers such as
proteins and carbohydrates are degraded in the digestive tract via enzymes. Little
information is known on the metabolic processes of nanoparticles and their components.

Excretion
Nanoparticles can also pass by the epithelial cells and mucus without being absorbed; if
this happens, nanoparticles enter the colon directly, and they are prepared for excretion.
From the liver, the nanoparticles may also reenter the intestines for excretion (Lu et al.
2010). Hydrophilic particles may be excreted through the kidneys into the urinary tract if
they are smaller than 10 nm (Choi et al. 2011) (Figure 3).
Nanoparticles can be designed to improve absorption, enhance distribution, and reduce
excretion (Table 2). Neutrally charged, hydrophobic nanoparticles that are smaller than
100 nm are
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Table 2: Optimal characteristics of nanodelivery systems for improved absorption,
distribution, and excretion

ideal for absorption. Neutrally charged, hydrophilic nanoparticles that are smaller than
100 nm remain in circulation longer, making them ideal for distribution. Hydrophilic
nanoparticles smaller than 5 nm are excreted via the kidneys. Nanoparticles larger than
500 nm are not likely absorbed in the intestines and are excreted in the feces.

Fate of Bioactives
The entrapped bioactive is eventually released into the body either in the intestines,
during systemic circulation, or in the cells of organ tissues (Bouwmeester et al. 2009,
Chen et al. 2011). The surface chemistry of the nanodelivery system is responsible for the
time and location of the release. Release can be stabilized through the use of polymers
such as alginate or chitosan, which are applied in a layer-by-layer technique to prevent a
burst release (Quintanilla-Carvajal et al. 2009).
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The location of release can be controlled through the use of polymers that are sensitive to
a specific pH range. For example, PEG has been shown to increase pH-stimulated
lysozyme release (Quintanilla-Carvajal et al. 2009).
If released into the intestines, the bioactive will undertake intracellular trafficking into
enterocytes or M cells. The chemical, morphological, and physical properties of the
bioactive will deter- mine the rate, method, and gravity of uptake (Sahay et al. 2010).
Non-ionic hydrophobic bioactives will be taken up in greater quantities than charged or
hydrophilic molecules (Florence 2005). The bioactive may remain in the intestinal cells;
it may be released into the lymphatic system, or it may be released into a portal vein
routing it to the liver (Hunter et al. 2012, Markovsky et al. 2012).
If released into systemic circulation, the properties of the bioactive will determine how it
interacts with blood components. A hydrophilic non-ionic bioactive will remain in
circulation longer than a hydrophobic bioactive due to the hydrophobic and electrostatic
interactions required for plasma proteins to bind to molecules (Sheng et al. 2009).
If released into the cells of organ tissues, cellular interactions will determine the
intracellular trafficking of the bioactive (Sahay et al. 2010). The method of entry the
nanoparticle employed to enter the cell will determine the location of bioactive release. If
lysosomal release occurs, small hydrophobic molecules are able to escape the endosome
or lysosome membranes, and large or hydrophilic molecules will remain inside the
lysosomes (Romberg et al. 2008). Bioactives may follow the pathways of typical watersoluble or fat-soluble biomacromolecules depending on their chemical and physical
properties (Sahay et al. 2010).

	
  

25	
  

	
  

Safety Of Nanoparticles For Bioactive Delivery
Nanotechnology application in the food and agriculture sectors has been hindered to
some extent by concerns about the safety of the engineered nanoparticle (ENP), as well
as ethical, policy, and regulatory issues (Food Agric. Org. & World Health Org. 2012),
all rooted in the lack of knowledge about the potential effects of nanomaterials on human
health and the environment. Large differences in the toxicokinetic properties for ENPs of
varying types are expected (European Com- mission 2009). Even for the same type of
ENP, when nanoparticles do not show any acute toxicity, questions of long-term effects
and bioaccumulation remain unanswered (Tiede et al. 2008). For poly(lactic-co-glycolic)
acid (PLGA) ENPs, making up a well-studied biodegradable and biocompatible
polymeric delivery system, little to no histopathological changes were found in tissues
derived from animals treated orally with PLGA nanoparticles. For example, high doses of
PLGA ENPs (4 mg/0.2 ml) did not lead to any tissue lesions as compared to the same
high dose of ZnO nanoparticles that led to toxicity in Balb/C mice (Semete et al. 2010).
Similarly, in Sprague Dawley rats, histopathological examination of tissue indicated
absence of any inflammatory response in the liver and spleen (Mittal et al. 2007).
Cationic bovine serum albumin–PLGA ENPs showed mild
and transient inflammatory reactions in the liver and kidney; mild reactions in the spleen;
and no reaction in the cerebral cortex, hippocampus region, cerebellum, lung, or heart
(Lu et al. 2007).To date, little work has been done in vivo to evaluate the fate of
polymeric nanoparticles purposely designed for food and agricultural uses (European
Commission 2009) and to correlate with the fate of nanoparticles after ingestion with
their possible toxic effects. The challenge for characterizing nanoparticles with regard to
human toxicity is due to the diversity of the size, shape, and surface chemistry
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(Elder et al. 2009) of ENPs. In addition, agglomeration, degradation, and mucus
interaction of particles as a function of ENP material composition and surface
characteristics will dictate the ADME profile of the ENPs and inherently ENP safety.
Nanoparticles made of food grade materials, intended specifically for food and
agriculture uses, are expected to be nontoxic to the animal host on the premise that the
materials used in the ENP synthesis are carefully selected to hold generally-recognizedas-safe status. Yet, ENP safety to humans and farm animals exposed to nanoparticles is a
major concern, and understanding the effect of the particle type and properties on the fate
of the nanoparticle in the GI tract, of ENP uptake, and of biodistribution as well as the
potential toxic effects is critically important for the responsible development and use of
ENPs in food and agriculture.
Toxicological studies provide information on carcinogenicity, teratogenicity,
reproductive toxicity, developmental toxicity, and neurotoxicity of the nanoparticle prior
to their use (Cockburn et al. 2012). Cockburn et al. proposes a two-tiered system for
engineered nanomaterial (ENM) safety characterization, where in silico, in vitro, and
subacute in vivo studies comprise tier 1 and acute in vivo studies make up tier 2. In tier 1,
the beginning criteria to evaluate engineered nanodelivery systems are biodegradability,
biocompatibility, and solubility compared to their microscale counterparts.

The metabolism and elimination profiles of the nanomaterial are important factors to
consider in preventing accumulation of the nanodelivery systems in tissues and clearance
organs (Markovsky et al. 2012). In silico studies provide computed data describing the
potential toxicity and ADME profile. In vitro studies use real or simulated biological
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material to determine possible cytotoxicity, genotoxicity, reactive oxygen species
generation, inflammatory response, and chemical degradation of nanomaterials. In vivo
studies offer data on toxicity, genotoxicity, and the ADME profile; for tier 1, the
suggested timeline for in vivo repeat dosing is 14 or 28 days (Cockburn et al. 2012). In
tier 2, the dosing time for in vivo studies increases to an acute dose time of 90 days to
determine carcinogenicity, reproductive toxicity, neurotoxicity, and teratogenicity
(Cockburn et al. 2012).
Safe application of nanoparticles to food and agriculture requires the nanoparticle
characterization, functionality, ADME profile, and toxicity to be determined. A tiered
approach to ENM testing provides a means to establish the type and quantity of
toxicological studies necessary to determine safety.

Conclusion
Nanodelivery systems offer a multitude of physical and chemical advantages for
improved bioavailability and stability of bioactives. Each type of nanodelivery system
offers distinct benefits, and the properties of the bioactive along with the purpose of
delivery should determine which nanoparticle type is most appropriate for the
application. The system’s chemical, physical, and morphological properties will
determine the nano-bio interaction and ADME profile. Properties of importance for
cellular and immunological interaction are size, charge, hydrophobicity, and targeting
molecules. Degradation in the stomach (low pH, presence of enzymes), the presence of
the firmly adherent mucosal lining, selectively permeable epithelial and M-cell
membranes, as well as enzymatic degradation in the intestines hinder uptake of the
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nanodelivery system and bioactive absorption. Upon absorption, the nanodelivery system
must evade the MPS, which will remove nanoparticles from systemic circulation.
Distribution of the nanodelivery system begins once nanoparticles enter systemic
circulation through the lymph or caudal vena cava. The fate of the bioactive greatly
depends on where it is released, but it also depends on its chemical, physical, and
morphological properties. The location of bioactive release can be tailored using nanomaterials with specific surface chemistry, enabling release at the target. A layer-by-layer
approach for engineering the nanodelivery system prevents the burst release of the
bioactive and ensures a gradual release profile of the bioactive. The safety of
nanodelivery systems is determined by the materials’ biocompatibility, biodegradability,
and nanoparticle ADME profile. A combination of in silico, in vitro, and in vivo studies
reveals the safety and toxicological profile of the nanodelivery system and is required for
the safe application of nanodelivery systems in food and agriculture.

Summary Points
1. Nanodelivery of food bioactives enhances their bioavailability and biodistribution
through the improvement of their uptake, stability, and solubility.
2. Nanodelivery systems are classified into two main groups, liquid and solid. Liquid
particles can be nanoemulsions, nanoliposomes, or nanopolymersomes. Solid particles
consist of nanocrystals, lipid particles, or polymeric particles.
3. Physicochemical properties of importance for nano-bio interaction include nanoparticle
size, charge, hydrophobicity, and targeting molecules, among others. Size is important for
nanoparticle entry into cells, immune system interactions, and nanoparticle clearance.
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Hydrophobicity affects absorption, distribution, interaction with immune cells and
plasma proteins, and route of excretion. Charge is important for mucoadhesion
or diffusion, cellular uptake, and toxicity. Targeting affects biodistribution and immune
responses.
4. Orally delivered nanoparticles must overcome the chemical and physical barriers to absorption, which include the acidic pH of the stomach and enzymes, the loosely and firmly
adherent mucosal linings of the intestines, and selectively permeable enterocyte
membranes.
5. The entrapped bioactive is eventually released in the intestines, in the circulatory
system, or in the cells of various organs. The location of release and the chemical and
physical properties of the bioactive determine its biological fate.
6. The safe application of nanoparticles in food and agriculture require knowledge of
their ADME and toxicological profiles.
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CHAPTER 3: ANTIOXIDANT ACTIVITY OF ENTRAPPED LUTEIN
Introduction
Unsaturated fatty acids and lipids are a prime target of oxidation in foods and biological
systems (Laguerre, Lecomte et al. 2007). Macular degeneration and cataracts, UV
induced sun damage, and risk of atherosclerosis can be decreased by enhanced
consumption of foods or supplements containing lutein (Kritchevsky, Bush et al. 2000;
Dwyer, Navab et al. 2001; Krinsky, Landrum et al. 2003; Alves-Rodrigues and Shao
2004; Lee, Faulhaber et al. 2004).
Lutein, a dietary antioxidant (Figure 3.1), is essential for diminishing photo-induced
oxidative stress and is useful for filtering high energy blue light in the lens and macula
lutea in the retina (Alves-Rodrigues and Shao 2004; Ahmed, Lott et al. 2005).

OH

HO

Figure 3.1 Lutein Structure
Lutein is reactive at quenching both singlet oxygen radicals, formed through UV
photonic exposure (Laguerre, Lecomte et al. 2007), and peroxyl radicals, which result
from the oxidation of unsaturated fatty acids (Kiokias and Oreopoulou 2006). Singlet
oxygen radicals are electrophilic and form hydroperoxides, which break down into
radicals causing autoxidation of lipids. Hydroxyl, hydroperoxyl, peroxyl, and lipid
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alkoxyl radicals are mainly responsible for non-enzymatic lipid oxidation, which results
in the formation of toxic hydroxy and ketocholesterols (Laguerre, Lecomte et al. 2007;
Lordan, Mackrill et al. 2009). In the macula lutea of the eye, cholesterol is photooxidized
to 7-ketocholesterol and 7α and β-hydroxycholesterols, process linked to macular
degeneration (Breuer, Dzeletovic et al. 1996; Rodriguez and Larrayoz 2010).
Lutein is easily oxidized by photooxidation or free radicals; therefore providing a
means of improving its chemical stability until use would preserve the efficacy of the
antioxidant (Lakshminarayana, Aruna et al. 2008). Release of preserved antioxidant over
time, providing radical scavenging benefits for extended periods of time, would further
aid in enhancing its activity for long-term applications.
Nanodelivery systems have been proposed as alternatives for improving stability,
release and functionality of bioactives. It has been shown for example that chemical
stability of quercetin, alpha-tocopherol, and beta-carotene was protected using chitosan
and solid lipid nanoparticles (Trombino, Cassano et al. 2009; Luo, Zhang et al. 2010),
while PLA, PLGA, and zein nanoparticles were previously developed to provide
controlled release of other hydrophobic drugs and antioxidants (Kumari, Yadav et al.
2010; Hu, Liu et al. 2011; Hu, Lin et al. 2012). Of the studies focused on entrapping
antioxidants in nanoparticles many are centered on nanoparticle characteristics,
antioxidant stability and release, and very few on the effect of the delivery system on the
efficacy of the antioxidant (Bala, Bhardwaj et al. 2006; Pool, Quintanar et al. 2012).

The goal of this study was to determine if stability and antioxidant activity of
lutein could be improved by entrapping the bioactive into polymeric nanoparticle of
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different surface properties. The hypothesis of this study was that by providing controlled
release and protection from degradation of entrapped lutein into polymeric nanoparticles
made of poly(lactic-co-glycolic) acid ( PLGA) will improve its antioxidant activity.
Furthermore, it was hypothesized that the addition of chitosan on the nanoparticle surface
will enhance the antioxidant efficacy by acting as a co-antioxidant; chitosan like lutein is
a singlet oxygen scavenger (Xie 2001; Xing, Liu et al. 2005; Yen, Yang et al. 2008).
Two nanoparticle types of a similar size, PLGA (lutein) and PLGA/Chitosan
(lutein), were used in this study. The particles differed in surface charge due to the
positively charged chitosan on the surface of PLGA/Chitosan (lutein) NPs. Release and
degradation of lutein were assessed in Tween 20 emulsions in the presence and absence
of the chemical initiator, 2,2′-azobisamidinopropane dihydrochloride (AAPH) using
spectrophotometry. Antioxidant activity was evaluated using a cholesterol assay to
determine the effect of NP entrapment on the antioxidant efficacy of lutein.

Materials and Methods
Materials: PLGA (50:50; Mol. Wt. 30,000-60,000) was purchased from Sigma Aldrich
(St. Louis, Missouri). Koumin Foods, LLC (Des Moines, IA) provided lutein. Poly (vinyl
alcohol) (PVA; Mol. Wt. 9000), ethyl acetate, acetonitrile, (2,2′-azobisamidinopropane
dihydrochloride) AAPH, Tween 20, and all other chemicals were purchased from Sigma
Aldrich (St. Louis, Missouri).

Synthesis: Poly (D, L-Lactide-co-glycolide) nanoparticles (NPs) with entrapped lutein
and blank polystyrene NPs (as a control) were prepared using emulsion evaporation. The
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organic phase was made up of 200 mg of PLGA and 20 mg of lutein (10% loading),
which were dissolved in 8mL of ethyl acetate. The organic phase was added via a syringe
to 40mL of an aqueous phase containing 2% w/v PVA in deionized water and 4 mL of
ethyl acetate at 300 rpm. The emulsion was run three times through the microfluidizer at
30000psi for uniform size reduction. Solvent evaporation occurred under vacuum (70 mm
Hg) for 60 minutes by rotovap (Buchi R-124, Buchi Analytical Inc., New Castle, DE,
USA). Residual lutein and PVA were removed through dialysis membranes with
MWCO: 100,000 Daltons. PLGA/Chitosan NPs were made by adding low molecular
weight chitosan to PLGA NPs after dialysis under stirring at a pH of 3 in a ratio of 1:10,
Chitosan to PLGA. Polystyrene NPs were made exactly as PLGA NPs without the
addition of lutein. After dialysis, trehalose was added in a (1:1) w/v ratio, and particles
were lyophilized using Freezone 4.5 (Labconoco Corp., Kansas City, MO, USA) for 72
hours. Freeze dried particles were stored at 0°C until analysis.
Size Analysis and Morphology: Hydrodynamic radius, size distribution, and
polydispersity index was determined by dynamic light scattering with a Zetasizer
(Malvern Instruments, Malvern, UK). Transmission electron microscopy (TEM) was
used for morphology studies of the particles. Zeta potential was also measured with the
Zetasizer using the Helmholtz-Smoluchowski equation.
Entrapment: Extraction was performed to remove entrapped lutein from nanoparticle
powder. An amount of 6 mg of powder was suspended in 600 µL of water using
sonication and next 5.4 mL of acetonitrile was added. The mixture was allowed to set for
4 hours, and the 6 mL sample was centrifuged at 30,000 rpm for 15 minutes at 8 ° C. The
absorbance of the supernatant was measured on a UV-Vis spectrophotometer (Genesys 6,
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Thermo Fisher Scientific, Waltham, MA) at 450 nm for detection of lutein. The
absorbance value was used to calculate the concentration of lutein entrapped using a
standard curve. The limit of detection on the spectrophotometer for lutein was calculated
to be 3.8 µg/mL.
Cholesterol Oxidation: An emulsion was made with 1000 mg of cholesterol with 10 mL
of tween 20 in one liter of nanopure water. AAPH was used as an initiator at a
concentration of 100 ppm. Each lutein sample was mixed with 27 mL of the cholesterol
solution and 3 mL of AAPH for a final lutein concentration of 94 µM. The solution was
continuously stirred for 72 hours at 37 °C as a model for human body temperature.
Samples were taken for HPLC analysis at 0, 24, 48, and 72 hours to determine the level
of 7-ketocholesterol, the oxidation product of cholesterol. The HPLC analysis method
used for 7-ketocholesterol determination was obtained from Xu et al. (Xu, Hua et al.
2001). A 1 mL sample was taken and mixed with hexane. Centrifugation at 5,000g for 10
minutes was performed to remove the aqueous portion of the sample. Sodium sulfate
was used to further remove any moisture before injecting the sample. The sample was
analyzed using a Waters 2690 separation module with a silica normal phase column and a
mobile phase of hexane: isopropanol (99%: 1%) was used at a 1.5 mL/min flow rate.
Detection of 7-ketocholesterol (UV wavelength of 234 nm) was done using a 996photodiode array detector and a Millennium chromatography station (Milford, MA). The
concentration was calculated using a standard curve of 7-ketocholesterol (Tian, Wang et
al. 2011).
Physical Stability of lutein-loaded nanoparticles in emulsion environments: The physical
stability of NP, with entrapped lutein in the cholesterol emulsions was assessed using the
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Zetasizer (Malvern Instruments, Malvern, UK). Change in size, PDI, and zeta potential of
the NPs were monitored for 72 hours in the cholesterol emulsion using the methods
described above. Chemical stability of lutein emulsified and entrapped in PLGA (lutein),
and PLGA/Chitosan (lutein) nanoparticles was measured for up to 24 hours in emulsions
with and without AAPH.
Localization in the emulsion environment: Confocal imaging was used to determine the
localization of NP lutein in the linolenic acid emulsion. Linolenic acid emulsion droplets
were stained using oil red (excitation: 589 nm, emission: 615 nm). Fluorescently labeled
PLGA with fluorescein isothiocyanate, FITC, (excitation: 495 nm, emission: 519 nm)
were used in this study. All images were taken using a Leica TCS SP2 Spectral Confocal
Microscope (Buffalo Grove, IL).
Statistical Analysis: All experiments were performed in triplicate, and all data was
analyzed for statistical difference (Adj P < 0.05) using the PROC MIXED with the
Tukey-Kramar adjustment Procedure in SAS 9.3 (SAS Instistute Inc. Cary, NC).

Results
Size, Morphology, Zeta Potential and Remaining PVA analysis:
PLGA (lutein) NPs measured 119 nm ± 0.98 nm in size, and PLGA/Chitosan (lutein) NPs
were 146 ± 3 nm in diameter when measured in nanopure water (Table 3.1) with PDIs of
0.17± 0.02 and 0.25 ± 0.01, respectively. Zeta potentials in nanopure water of PLGA
(lutein) NPs and PLGA/Chitosan (lutein) NPs were -29 ± 1 and 21 ± 2 mV, respectively
(pH 6.8). The remaining PVA surfactant after dialysis was corresponding 11 ± 1 and 10 ±
1% of PLGA (lutein) and PLGA/Chitosan (lutein) NP structure, respectively. Based on
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TEM pictures, PLGA(lutein) NPs appeared to be spherical and uniform in size, while
PLGA/Chitosan (lutein) NPs appeared to be nearly spherical with a rough outer coating
(Figure 3.2). Entrapment efficiency measurements revealed that 21.8 ± 0.63 µg and 20.2
± 0.62 µg lutein per mg of nanoparticles was entrapped in the PLGA (lutein) and
PLGA/Chitosan (lutein) nanoparticles, respectively.

Table 3.1 Nanoparticle physical/chemical properties, including size, polydispersity, zeta
potential and surfactant concentration for PLGA and PLGA/Chitosan nanoparticles with
entrapped lutein

Nanoparticle
Type

Size (nm)

PDI (units)

Zeta Potential
(mV)

PVA Surfactant
(mg PVA/mg Particle)

PLGA (Lutein)

119.2 ±
0.98

0.17 ± 0.02

-29 ± 1.10

0.05 ± 0.00

PLGA/Chitosan
(Lutein)

145.9 ± 3

0.25 ± 0.01

+21.2 ± 2.30

0.06+ 0.00

A) PLGA (lutein)

B) PLGA/Chitosan

(lutein)
Figure 3.2: TEM images of A) PLGA (lutein) and B) PLGA/Chitosan (lutein) NPs
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Physical stability of NPs at 37 °C in the presence of Tween 20 emulsions was evaluated
using DLS, as these conditions were employed for cholesterol oxidation experiments.
PLGA and PLGA/Chitosan NPs with entrapped lutein remained stable for 24 hours in the
tween emulsion (Figure 3.3). Sizes increased at 48 hours and retained the larger size until
72 hours, but size changes over time were not found statistically different (Figure 3.3).

Figure 3.3: Size Stability of NPs in Tween Emulsions at 37°C

Lutein chemical stability was determined by measuring the amount of lutein present in
the NP over time at 37 °C in the presence and absence of a radical initiator, AAPH.
Chemical stability of NP entrapped lutein was compared to a Tween 20 lutein emulsion.
In the presence of AAPH, 71% ± 15% of the lutein remained after 12 hours, and 50% ±
30% remained after 24 hours in the emulsified form, whereas in the PLGA (Lutein) NP
emulsion, 81% ± 3% of the lutein was still available after 12 hours, and 65%± 10% after
24 hours. In the PLGA/Chitosan (lutein) NP emulsion 84% ± 7% lutein was preserved
after 12 hours, and 60% ± 28% after 24 hours (Figure 3.4 A). These changes over time
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were not statistically significant. In the absence of AAPH, 0% of lutein in emulsified
lutein, PLGA (lutein) NPs and PLGA/Chitosan (lutein) NPs was degraded over 24 hours
(Figure 3.4 B).

A)	
  

B)	
  

Figure 3.4: Chemical Stability of lutein in Tween Emulsions in the A) presence and B)
absence of AAPH at 37 °C: Results are reported as the percentage of lutein remaining in
the NP or in the emulsion at 12 and 24 hours.
Release of lutein from the nanoparticles suspended in the cholesterol emulsions
was examined and PLGA NPs showed 50% release of lutein after 24 hours and 89%
release after 72 hours. PLGA/Chitosan NPs showed 23 % release of lutein after 24 hours
and 69% release after 72 hours from PLGA NPs. The change in percent of lutein release
was statistically significant for each time point and was statistically different between
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PLGA (lutein) and PLGA/Chitosan (lutein) NPs (Figure 3.5) with more lutein being

%	
  of	
  Lutein	
  Released	
  

released from PLGA (lutein) than from PLGA/Chitosan (lutein) NPs.
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Figure 3.5: Release of Lutein in Cholesterol Emulsion: PLGA NPs and PLGA/Chitosan
NPs over 72 hours

Cholesterol Oxidation
Cholesterol oxidation results in the formation of 7-ketocholesterol; this compound can be
extracted and measured using normal-phase high-pressure liquid chromatography.
Presence of 7-ketocholesterol is associated with a low effectiveness of entrapped lutein as
an antioxidant and can be used to determine lutein antioxidant activity over time. 7ketocholesterol concentrations are shown for blank control and lutein treatments at 24,
48, and 72 hours (Figure 3.6).
No statistical difference was found between the unloaded treatments and the control at 24
hours (Figure 3.6 A). Polystyrene NPs showed no difference in the amount of 7ketocholesterol present after 24, 48, and 72 hours when compared to the blank control,
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whereas blank PLGA significantly reduced the oxidation of cholesterol at 72 hours and
PLGA/Chi unloaded nanoparticles significantly inhibited cholesterol oxidation at 48 and
72 hours (Figure 3.6 A). At 24 hours no statistical significance was found between lutein
loaded treatments, free lutein, and control (Figure 3.6 B). Lutein, PLGA (lutein), and
PLGA/Chitosan (lutein) showed significantly lower concentrations of 7-ketocholesterol
at 48 hours versus the control. PLGA/Chitosan (lutein) was significantly lower than
lutein at 48 and 72 hours when compared to the control (Figure 3.6 B).

*	
  

*	
  

*	
  

A)	
  
*A	
  
*A	
  

*AB	
  

*A	
  
*A	
  
*AB	
  

B)	
  
Figure 3.6 A): 7-Ketocholesterol Concentrations at 37 °C for Blank NP Treatments: 24,
48, and 72 hours * Empty PLGA and PLGA/Chitosan significantly lower than Control B)
7-Ketocholesterol Concentrations at 37 °C for Lutein NP Treatments: 24-Hours, 48
hours, and 72 hours *A Lutein, PLGA(lutein), PLGA/Chitosan (lutein) significantly
lower than control *AB PLGA/Chitosan (lutein) significantly lower than lutein
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Discussion
PLGA and PLGA/Chitosan nanoparticles with entrapped lutein were synthesized by
emulsion evaporation method, using poly (vinyl alcohol) as a surfactant. All particles
were determined to have a similar size, but differed in zeta potential due to the addition
of positively charged chitosan. Stability, release and antioxidant activity of lutein were
assessed in Tween 20 emulsions. Lutein stability in the presence and absence of the
chemical initiator, 2,2′-azobisamidinopropane dihydrochloride (AAPH) and lutein release
were assessed using spectrophotometry. Antioxidant activity of free and entrapped lutein
was evaluated by cholesterol oxidation analysis to assess the effect of entrapment and
nanoparticle properties on the activity of the bioactive.
PLGA (119.2 nm) and PLGA/Chitosan (145.9 nm) nanoparticles loaded with 21.8 ± 0.63
and 20.2 ± 0.62 µgs lutein/ mg NP, respectively were used in these studies. In terms of
size stability over time, PLGA nanoparticle size increased by 30 nm over the 72 hour
period, and the PLGA/chitosan nanoparticle size increased by 50 nm over the 72 hour
period at 37 °C, but the difference was not found statistically significant. Overall,
nanoparticles maintained their size stability over time under conditions relevant for
antioxidant experiments. Chemical stability of lutein was tested in the presence and
absence of the oxidizing agent, AAPH. In the absence of AAPH, 0% of entrapped and
free lutein was degraded over 24 hours, as expected. The percentage of lutein degraded
after 24 hours in the presence of AAPH was not statistically different for emulsified
lutein, PLGA (lutein) and PLGA/Chitosan (lutein) due to the amount of lutein released in
this environment after 24 hours (Figure 3.5).
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The cholesterol assay based on the measurement of 7-ketocholesterol, the final oxidation
product of cholesterol oxidation by radicals was used to measure antioxidant activity of
entrapped lutein. Cholesterol, an unsaturated lipid, undergoes the same three-stage
oxidation process as unsaturated fatty acids (Laguerre, Lecomte et al. 2007). The double
bond at carbons 5,6 make cholesterol easier to oxidize than other unsaturated lipids
(Iuliano 2011). Oxysterols are seen as end products of radical chain reactions with
cholesterol (Iuliano 2011). The final end product of non-enzymatic cholesterol oxidation
is 7-ketocholesterol, 3% -hydroxycholest-5-en-7-one, which results from the addition of a
ketone group to carbon 7 (Iuliano 2011).
Based on cholesterol oxidation experiments, all PLGA and PLGA/Chitosan nanoparticles
acted as antioxidants by significantly reducing the oxidation of cholesterol. In order to
determine whether this occurred via the physical presence of the nanoparticles or via
chemical reactions of the nanoparticles confocal microscopy was performed. Imaging
showed that PLGA nanoparticles moved throughout the emulsion independently from the
emulsion droplets (data not shown) therefore proving that protection from oxidation was
not simply the result of a NP physical association with the emulsion droplets, but rather
the chemical composition of the nanoparticle. To further prove this, polystyrene
nanoparticles were included in the study as a control in the cholesterol experiment. The
polystyrene nanoparticles did not show any antioxidant activity (Figures 3.6A), clearly
indicating that the antioxidant properties of PLGA and PLGA/Chitosan nanoparticles
were associated with chemical activity of the materials making the delivery systems or
the antioxidant loaded in the nanoparticles. The free carboxylic acid end groups of PLGA
or the positively charged amine groups of chitosan may have contributed to the
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antioxidative effects of the NPs through hydrogen donation, explaining the lack of
antioxidant activity of polystyrene nanoparticles.
The lutein release (Figure 3.5) coincided with the increased antioxidant activity of lutein
over time (Figure 3.6B), for antioxidant activity improved as more lutein was released
over time. For example, PLGA/Chitosan (lutein) showed 23 % lutein release after 24
hours and 69%, a much higher release after 72 hours (Figure 3.5), significantly different
between all time points. It was therefore inferred that the significant reduction of
oxidation of cholesterol observed at 48 hours and not at 24 hours was due to the time
needed for the lutein to be released from the nanoparticle and to reach the interface of the
emulsion. After 48 hours, lutein, PLGA (lutein), PLGA/Chitosan, PLGA/Chitosan
(lutein) significantly reduced oxidation of cholesterol compared to the control, and
PLGA/Chitosan (lutein) significantly reduced oxidation compared to the unentrapped
lutein control (Figure 3.6B).
After 72 hours, the treatments of lutein, PLGA, PLGA (lutein), and PLGA/Chitosan
(lutein) reduced the oxidation of cholesterol compared to the blank, but PLGA/Chitosan
(lutein) further reduced the oxidation compared to lutein and PLGA(lutein), which is
explained by the addition of chitosan (Figure 3.6B). Low molecular weight chitosan was
found to be a scavenger of singlet oxygen and hydroxyl radicals, so the addition of
chitosan should make a significant difference in antioxidant activity (Xie 2001; Xing, Liu
et al. 2005; Yen, Yang et al. 2008).
PLGA/Chitosan (lutein) NPs showed significantly better antioxidant activity than
PLGA/Chitosan at 72 hours, which is explained by the addition of lutein and the increase
in lutein release at this time.
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PLGA (lutein) and PLGA/Chitosan decreased the oxidation of cholesterol compared to
PLGA, which can be explained by the addition of material with antioxidant properties
lutein and chitosan.

Conclusions
In an effort to determine suitability of polymeric nanoparticles for delivery of
antioxidants, specifically lutein, the stability and antioxidant activity of lutein entrapped
in PLGA and PLGA/Chitosan NPs in comparison with unentrapped lutein, were
measured. Both PLGA and PLGA/Chitosan NPs with entrapped lutein maintained their
size throughout antioxidant experiments. PLGA and PLGA/Chitosan NPs did not
improve the chemical stability of lutein when compared to emulsified lutein in the
presence of AAPH. However, PLGA/Chitosan NPs improved the antioxidant activity of
lutein by 21% ± 1% at 48 hours and 21%± 3% at 72 hours compared to emulsified lutein
using the cholesterol assay (Figure 3.6B). Blank PLGA and PLGA/Chitosan NPs also
appeared to act as antioxidants in these experiments, whereas polystyrene NPs did not;
this suggested that blank PLGA and PLGA/Chitosan NPs improved the antioxidant
activity through chemical reactions rather than providing a physical barrier to oxidation.
It was concluded that entrapping lutein in PLGA and PLGA/Chitosan NPs did not
significantly improve lutein stability over that of free lutein, but due to the release of
lutein over time achieved by entrapping it in PLGA and PLGA/Chi nanoparticles, it
increased its antioxidant efficacy.
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The addition of materials of antioxidant activity such as chitosan to the nanoparticles
further improved the antioxidant activity of the nanoparticle system.

Future Experiments
The chemical mechanism by which unloaded PLGA and PLGA/Chitosan exhibited
antioxidant properties is not covered in the published literature. Additional studies
determining the effect of oxygen concentration and pH of the experimental environments
on cholesterol oxidation is important for determining the chemical mechanism of action
by which PLGA and PLGA/Chitosan prevented oxidation of cholesterol. Further
experiments testing effects of NP properties on antioxidant activity of entrapped lutein
could also provide a clearer understanding of the enhanced particle antioxidant activity of
nanodelivered lutein.
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CHAPTER 4. CONCLUSIONS
Nanodelivery systems offer many physical and chemical advantages for improved
functionality of entrapped bioactives; i.e. the addition of chitosan significantly improved
the antioxidant efficacy of lutein against the oxidation of cholesterol. Each type of
nanodelivery system offers distinct benefits, and the properties of the bioactive along
with the purpose of delivery should determine which nanoparticle type is most
appropriate for the application, i.e. nanodelivery systems for oral delivery should be
biodegradable and biocompatible. Lutein is one of the few carotenoids found in the retina
and is essential for diminishing photo-induced oxidative stress in the lens and macula
lutea in the retina (Alves-Rodrigues and Shao 2004), (Ahmed, Lott et al. 2005). Also in
the macula lutea of the eye, cholesterol is photooxidized to 7-ketocholesterol and the
process is linked to macular degeneration (Rodriguez and Larrayoz 2010), (Breuer,
Dzeletovic et al. 1996). Lutein was proven to significantly reduce the oxidation of
cholesterol to 7-ketocholesterol, and PLGA/Chitosan (Lutein) was found to improve this
effect when compared to lutein after 48 hours of oxidation. Further studies should be
done to determine the nano-bio interaction, bioavailability, and ADME profile of
PLGA/Chitosan (lutein) compared to free lutein in order to determine if PLGA/Chitosan
(Lutein) as a nanodelivery system could improve the efficacy of lutein as a treatment for
macular degeneration.
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APPENDIX
3.1 Lutein Standard Curve: All lutein concentrations were calculated using a lutein
standard. The absorbance was measured on a UV-Vis spectrophotometer (Genesys 6,
Thermo Fisher Scientific, Waltham, MA) at 450 nm.
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3.2 PVA Standard Curve: All NP PVA Concentrations were calculated using a PVA
standard. The absorbance was measured on a UV-Vis spectrophotometer (Genesys 6,
Thermo Fisher Scientific, Waltham, MA) at 690 nm.
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3.3 Size Stability in Cholesterol and Linolenic Acid Emulsions: Size in (nm) and Zeta
Potential in (mV) and of PLGA and PLGA/Chitosan (lutein) NPs at 0, 24, 48 and 72
hours.
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3.4 Cholesterol Oxidation: 7-ketocholesterol Concentrations 0, 24, 48, and 72 hours and
% Inhibition at 24, 48, and 72 hours.

Appendix 3.5: Cholesterol Oxidation from 0 è72 Hours: The general trend of 7ketocholesterol increase between the treatments is depicted in this graph.
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3.6 SAS Programs
3.6A: Size Stability
Title 'Size Stability in Emulsion';
Proc Mixed data=work.SIZEE;
Class NP Beaker Time;
Model Y = NP|Time / outp= resids;
Random Beaker(NP) Beaker(NP*Time);
LSMeans NP|Time / adjust=tukey CL;
run;
Proc Univariate data = resids plot=normal;
var resid;
run;
PROC IMPORT OUT= WORK.SIZEE
DATAFILE= "C:\Users\snavar4\Documents\SAS1\EmulsionSizeStabi
lity.xlsx"
DBMS=EXCEL REPLACE;
RANGE="Sheet1$";
GETNAMES=YES;
MIXED=NO;
SCANTEXT=YES;
USEDATE=YES;
SCANTIME=YES;
RUN;

3.6 B: Chemical Stability
Title 'Lutein AND Cholesterol Chemical Stability in Emulsion Experiment';
Proc Mixed data=work.RELEASE;
Class NP Beaker Time;
Model Y = NP|Time / outp= resids;
Random Beaker(NP) Beaker(NP*Time);
LSMeans NP|Time / adjust=tukey CL;
run;
Proc Univariate DATA = resids plot = normal;
var resid;
run;
PROC IMPORT OUT= WORK.Release
DATAFILE= "C:\Users\tborel1\Documents\RELEASE.xlsx"
DBMS=EXCEL REPLACE;
RANGE="Sheet4$";
GETNAMES=YES;
MIXED=NO;
SCANTEXT=YES;
USEDATE=YES;
SCANTIME=YES;
RUN;
dm 'log; clear; output; clear';
options nodate;
ods html close;
ods html;
ods listing;
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3.6 C: Cholesterol Oxidation
dm 'log; clear; output; clear';
options nodate;
ods html close;
ods html;
ods listing;
Proc Mixed data=WORK.SASCHOL3;
Class REP TREATMENT BEAKER TIME;
Model POSTY = TREATMENT TIME (TREATMENT*TIME)/ output=resids;
Random REP(TREATMENT) BEAKER(TREATMENT) REP(TREATMENT*TIME)
BEAKER(REP*TREATMENT*TIME);
LSMeans TREATMENT TIME (TREATMENT*TIME)/ adjust=tukey CL;
run;
proc univariate data=resids plot normal;
Var resid;
run;

PROC IMPORT OUT= WORK.SASCHOL3
DATAFILE= "C:\Users\snavar4\Documents\SAS1\SASCD2.xlsx"
DBMS=EXCEL REPLACE;
RANGE="Sheet1$";
GETNAMES=YES;
MIXED=NO;
SCANTEXT=YES;
USEDATE=YES;
SCANTIME=YES;
RUN;
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